Theophylline

Generic Name: Theophylline

Brand Names: Elixophyllin, Elixophylline, Pulmophylline, Quibron-T, Theo-24, Theolair, Uniphyl

Drug Type: Small Molecule

Chemical Formula: C_₇H_₈N_₄O_₂

CAS Number: 58-55-9

Unique Ingredient Identifier: 0I55128JYK

Background: A methylxanthine derivative from tea with diuretic, smooth muscle relaxant, bronchial dilation, cardiac and central nervous system stimulant activities. Mechanistically, theophylline acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator. Theophylline is marketed under several brand names such as Uniphyl and Theochron, and it is indicated mainly for asthma, bronchospasm, and COPD.

Indication: For the treatment of the symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, such as emphysema and chronic bronchitis.

Associated Conditions: Asthma, Bronchitis, Bronchoconstriction, Bronchospasm, Chronic Obstructive Pulmonary Disease (COPD), Chronic bronchial inflammation

Associated Therapies: Airway secretion clearance therapy, Bronchodilation

Clinical Trials

Theophylline Treatment for Pseudohypoparathyroidism

Phase 2

Recruiting

Conditions: Pseudohypoparathyroidism
Albright Hereditary Osteodystrophy

Interventions: Drug: Theophylline
Drug: Placebos

First Posted Date: 2017-01-24

Last Posted Date: 2024-04-02

Lead Sponsor: Vanderbilt University Medical Center

Target Recruit Count: 34

Registration Number: NCT03029429

Locations: 🇺🇸
Ashley Shoemaker, Nashville, Tennessee, United States

Association Study Between CYP1A2 Gene Polymorphisms and Metabolism of Theophylline

Not Applicable

Completed

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: Theophylline

First Posted Date: 2017-01-09

Last Posted Date: 2022-03-17

Lead Sponsor: XiaoGuang Zou

Target Recruit Count: 110

Registration Number: NCT03015090

Locations: 🇨🇳
Kashgar 1st People's Hospital, Kashgar, Xinjiang, China

Longitudinal Cohort Study in Participants With Severe Asthma to Assess Biomarkers

Phase 4

Completed

Conditions: Asthma

Interventions: Drug: FP
Drug: LABA
Drug: LTRA
Drug: LAMA
Drug: Theophylline
Drug: Oral Corticosteroids

First Posted Date: 2015-09-02

Last Posted Date: 2019-04-09

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 483

Registration Number: NCT02537691

Locations: 🇱🇻
Riga 1st hospital, outpatient clinic Bruninieks, Riga, Latvia
🇱🇻
Clinical Hospital Gailezers; Dept of Pulmonology, Riga, Latvia
🇱🇻
Latvian University postgraduate institute, Riga, Latvia

and more 97 locations

Helping Olfaction and Nutrition On Renal Replacement

Phase 2

Completed

Conditions: Olfactory Disorders
End Stage Renal Disease

Interventions: Drug: Theophylline

First Posted Date: 2015-06-24

Last Posted Date: 2024-01-09

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 7

Registration Number: NCT02479451

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Theophylline as a Treatment for Children With Pseudohypoparathyroidism Type 1a (Albright Hereditary Osteodystrophy)

Phase 2

Completed

Conditions: Pseudohypoparathyroidism Type 1a
Albright Hereditary Osteodystrophy

Interventions: Drug: Theophylline

First Posted Date: 2015-06-04

Last Posted Date: 2017-06-26

Lead Sponsor: Vanderbilt University Medical Center

Target Recruit Count: 6

Registration Number: NCT02463409

Locations: 🇺🇸
Vanderbilt Unversity, Nashville, Tennessee, United States

Enhancement of Corticosteroid Efficacy in COPD

Phase 3

Completed

Conditions: COPD

Interventions: Drug: Theophylline
Drug: Roflumilast

First Posted Date: 2015-01-16

Last Posted Date: 2018-06-19

Lead Sponsor: UConn Health

Target Recruit Count: 13

Registration Number: NCT02340520

Locations: 🇺🇸
UConnHealth, Farmington, Connecticut, United States

Effect of BIIL 284 BS on the Pharmacokinetics of Theophylline in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BIIL 284 BS
Drug: Placebo
Drug: Theophylline

First Posted Date: 2014-10-24

Last Posted Date: 2014-10-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 16

Registration Number: NCT02273440

Theophylline and Steroids in Chronic Obstructive Pulmonary Disease (COPD) Study

Phase 4

Completed

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: Placebo (for prednisone)
Drug: Theophylline
Drug: Placebo (for Theophylline)
Drug: Prednisone

First Posted Date: 2014-10-10

Last Posted Date: 2021-08-12

Lead Sponsor: The George Institute

Target Recruit Count: 1670

Registration Number: NCT02261727

Locations: 🇦🇺
The George Institute for Global Health, Sydney, New South Wales, Australia

Theophylline, N-acetylcysteine, and Theophylline Plus N-acetylcysteine in Preventing Contrast-induced Nephropathy

Phase 2

Conditions: Contrast-Induced Nephropathy

Interventions: Drug: N-acetylcysteine
Drug: Theophylline
Drug: 0.9% sodium chloride

First Posted Date: 2014-03-17

Last Posted Date: 2014-03-17

Lead Sponsor: Isfahan University of Medical Sciences

Target Recruit Count: 96

Registration Number: NCT02088502

Locations: 🇮🇷
Chamran Hospital, Isfahan, Iran, Islamic Republic of

A Phase I Dose Escalation Study of Erlotinib in Combination With Theophylline

Phase 1

Terminated

Conditions: Non-small Cell Lung Cancer
Advanced Solid Malignancies

Interventions: Drug: Theophylline
Drug: Erlotinib

First Posted Date: 2014-03-06

Last Posted Date: 2019-05-03

Lead Sponsor: AHS Cancer Control Alberta

Target Recruit Count: 15

Registration Number: NCT02080078

Locations: 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy